目的 探討脂必泰膠囊聯(lián)合普羅布考治療高脂血癥的臨床療效。方法 選擇2020年10月—2021年10月天津市南開醫(yī)院收治的80例高脂血癥患者，隨機(jī)分對照組（40例）和治療組（40例）。對照組患者口服普羅布考片，0.5 g/次，2次/d。在對照組的基礎(chǔ)上，治療組口服脂必泰膠囊，1粒/次，2次/d。兩組患者治療8周。觀察兩組患者臨床療效，比較治療前后兩組患者癥狀好轉(zhuǎn)時間，血脂低密度脂蛋白膽固醇（LDL-C）、總膽固醇（TC）、三酰甘油（TG）和高密度脂蛋白膽固醇（HDL-C）水平，血清因子白細(xì)胞介素-6（IL-6）、血清單核細(xì)胞趨化蛋白-1（MCP-1）、細(xì)胞間黏附分子-1（ICAM-1）和腫瘤壞死因子-α（TNF-α）水平，及不良反應(yīng)情況。結(jié)果 治療后，治療組臨床有效率（97.50%）明顯高于對照組（77.50%，P＜0.05）。治療后，治療組癥狀好轉(zhuǎn)時間明顯短于對照組（P＜0.05）。治療后，兩組TC、TG、LDL-C水平明顯降低，而HDL-C水平明顯升高（P＜0.05），且治療組血脂水平明顯好于對照組（P＜0.05）。治療后，兩組血清因子IL-6、MCP-1、TNF-α、ICAM-1水平明顯低于治療前（P＜0.05），且治療組明顯低于對照組（P＜0.05）。治療組不良反應(yīng)發(fā)生率（7.50%）明顯低于對照組（17.50%，P＜0.05）。結(jié)論 脂必泰膠囊聯(lián)合普羅布考治療高脂血癥效果良好，能有效改善血脂水平，并可減輕炎性反應(yīng)，且安全有效。

Objective To investigate the clinical effect of Zhibitai Capsules combined with probucol in treatment of hyperlipidemia. Methods Patients (80 cases) with hyperlipidemia in Tianjin NanKai Hospital from October 2020 to October 2021 randomly were divided into control (40 cases) and treatment (40 cases) group. Patients in the control group was po administered with Probucol Tablets, 0.5 g/time, twice daily. Patients in the treatment group were po administered with Zhibitai Capsules on the basis of the control group, 1 grains/time, twice daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical evaluation was evaluated, and the improvement time of symptom, the levels of blood lipid TC, TG, LDL-C and HDL-C, the levels of serum IL-6, MCP-1, TNF-α and ICAM-1, and adverse reaction in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group (97.50%) was significantly higher than that of the control group (77.50%, P < 0.05). After treatment, the improvement time of symptom in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the levels of TC, TG and LDL-C were significantly decreased, while the level of HDL-C were significantly increased in two groups (P < 0.05), and the level of blood lipid in the treatment group was significantly better than that in the control group (P < 0.05). After treatment, the serum levels of IL-6, MCP-1, TNF-α and ICAM-1 in two groups were significantly lower than those before treatment (P < 0.05), which in the treatment group was significantly lower than that in the control group (P < 0.05). The incidence of adverse reactions in the treatment group (7.50%) was significantly lower than that in the control group (17.50%, P < 0.05). Conclusion Zhibitai Capsules combined with probucol is effective in the treatment of hyperlipidemia, which can effectively improve the level of blood lipids, and can reduce inflammatory reaction, and safe and effective.

R972